Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Scemblix“
Suchtreffer
Begriffe & Kennungen
Scemblix
Eintrag öffnenScemblix · 4.1 Therapeutic indications · 1
Eintrag öffnenScemblix · 4.3 Contraindications · 1
Eintrag öffnenScemblix · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenScemblix · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenScemblix · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenScemblix · 4.5 · 7 Substrates of BCRP or OATP1B Co-administration of asciminib with a BCRP and OATP1B substrate (rosuvastatin)
Eintrag öffnenScemblix · 4.5 · CYP2C9 substrates Co-administration of asciminib with a CYP2C9 substrate (warfarin) increased S-warfarin AUCin
Eintrag öffnenScemblix · 4.5 · CYP3A4 substrates with narrow therapeutic index Co-administration of asciminib with a CYP3A4 substrate (midazo
Eintrag öffnenScemblix · 4.5 · Caution should be exercised during concomitant administration of asciminib at 200 mg twice daily with P-gp sub
Eintrag öffnenScemblix · 4.5 · Caution should be exercised during concomitant administration of asciminib at a total daily dose of 80 mg and
Eintrag öffnenScemblix · 4.5 · Caution should be exercised during concomitant administration of asciminib at a total daily dose of 80 mg with
Eintrag öffnenScemblix · 4.5 · Caution should be exercised during concomitant administration of asciminib at all recommended doses with BCRP
Eintrag öffnenScemblix · 4.5 · Caution should be exercised during concomitant administration of asciminib at all recommended doses with CYP3A
Eintrag öffnenScemblix · 4.5 · Caution should be exercised during concomitant administration of asciminib at all recommended doses with stron
Eintrag öffnenScemblix · 4.5 · Co-administration of asciminib at 80 mg once daily with an OATP1B, CYP3A4 and P-gp substrate (atorvastatin) in
Eintrag öffnenScemblix · 4.5 · Concomitant administration of asciminib 200 mg twice daily with medicinal products with a known risk of torsad
Eintrag öffnenScemblix · 4.5 · Concomitant administration of asciminib at 200 mg twice daily with CYP2C9-sensitive substrates and CYP2C9 subs
Eintrag öffnenScemblix · 4.5 · Medicinal products that may decrease asciminib plasma concentrations
Eintrag öffnenScemblix · 4.5 · Medicinal products that may have their plasma concentrations altered by asciminib
Eintrag öffnen